Rifampicin compared to isoniazid for preventing active TB in HIV-negative people at risk of developing active TB: Implications for public health
A Cochrane systematic review summarised the evidence and examines the implications for public health
Abstract
A Cochrane systematic review summarised the evidence for the effects of 4 regimens containing 6 courses of rifampicin or rifamycin-combinations compared to isoniazid given for 6 to 9 months on the development of active tuberculosis (TB), adherence, treatment-limiting adverse events, and hepatotoxicity in HIV-negative people with latent TB infection (LTBI) or at risk of developing active TB.
This work is sponsored by the Effective Healthcare Research Consortium via a grant from the UK Department for International Development.
Citation
M.S. Jawahar, Soumya Swaminathan. Rifamycin drugs as alternatives to standard isoniazid treatment to prevent active tuberculosis (TB) in HIV-negative people at risk of developing active TB: Implications for public health. Clinical Epidemiology and Global Health, Volume 2, Issue 1, April 2014, Pages 37-38